- Home
- ROIV vs VNO Comparison
ROIV vs VNO Comparison
Compare ROIV & VNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | VNO |
|---|---|---|
| Founded | 2014 | 1946 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 6.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | VNO |
|---|---|---|
| Price | $21.42 | $33.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | $24.31 | ★ $37.67 |
| AVG Volume (30 Days) | ★ 8.3M | 1.4M |
| Earning Date | 02-09-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 4.20 |
| Revenue | $20,329,000.00 | ★ $1,903,939,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $741.42 | $1.18 |
| P/E Ratio | ★ N/A | $8.17 |
| Revenue Growth | N/A | ★ 1.75 |
| 52 Week Low | $8.73 | $29.68 |
| 52 Week High | $23.47 | $45.37 |
Technical Indicators
Market Signals| Indicator | ROIV | VNO |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 42.58 |
| Support Level | $20.78 | $32.89 |
| Resistance Level | $22.21 | $33.85 |
| Average True Range (ATR) | 0.64 | 0.75 |
| MACD | -0.17 | 0.09 |
| Stochastic Oscillator | 26.56 | 35.91 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.